UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020764
Receipt number R000023911
Scientific Title Searching factors changing profile of adipose-derived Mesenchymal Stem Cells (MSC) in patients with cardiovascular disease.
Date of disclosure of the study information 2016/01/31
Last modified on 2020/02/18 17:47:56

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Searching factors changing profile of adipose-derived Mesenchymal Stem Cells (MSC) in patients with cardiovascular disease.

Acronym

Characterizing of adipose-derived MSC in patients with cardiovascular disease.

Scientific Title

Searching factors changing profile of adipose-derived Mesenchymal Stem Cells (MSC) in patients with cardiovascular disease.

Scientific Title:Acronym

Characterizing of adipose-derived MSC in patients with cardiovascular disease.

Region

Japan


Condition

Condition

Cardiovascular disease

Classification by specialty

Medicine in general Cardiology Endocrinology and Metabolism
Cardiovascular surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the profile of MSCs in adipose tissue of patients with cardiovascular disease.

Basic objectives2

Others

Basic objectives -Others

Although adipose tissue is known to be an ideal cell source of mesenchymal stromal/stem cells (MSCs), a promising candidate for autologous cell therapy of cardiovascular disease, it is still unclear whether clinical patients maintain therapeutic MSCs in their adipose tissue. In this study, we investigate what impacts on yield of therapeutic MSCs in adipose tissue of patients with cardiovascular disease.

Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Profile of surface antigens in adipose-derived MSCs
Regenerative capacity of cultured MSCs (in vitro)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Eligible patients are adult male or female receiving elective cardiac surgery, including coronary artery bypass grafting (CABG), aortic valve replacement (AVR), cardiac device implantation, etc.

Key exclusion criteria

Major exclusion criteria are emaciation, uncontrolled diabetes mellitus, maintenance hemodialysis, systemic inflammatory disease, malignant disease, and former irradiation therapy.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Masayuki
Middle name
Last name Takamura

Organization

Kanazawa University Graduate School of Medical Science

Division name

Disease Control and Homeostasis

Zip code

920-8641

Address

13-1 Takara-machi, Kanazawa 920-8641, Japan

TEL

81-76-265-2233

Email

oto0803inoue@gmail.com


Public contact

Name of contact person

1st name Oto
Middle name
Last name Inoue

Organization

Kanazawa University Graduate School of Medical Science

Division name

Disease Control and Homeostasis

Zip code

920-8641

Address

13-1 Takara-machi, Kanazawa 920-8641, Japan

TEL

81-76-265-2233

Homepage URL


Email

oto0803inoue@gmail.com


Sponsor or person

Institute

Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science

Institute

Department

Personal name



Funding Source

Organization

Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethical committee of Kanazawa University Hospital

Address

13-1 Takara-machi, Kanazawa 920-8641, Japan

Tel

81-76-265-2100

Email

rinri@adm.kanazawa-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

金沢大学附属病院 (石川県)


Other administrative information

Date of disclosure of the study information

2016 Year 01 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2014 Year 10 Month 26 Day

Date of IRB

2014 Year 11 Month 12 Day

Anticipated trial start date

2015 Year 04 Month 06 Day

Last follow-up date

2025 Year 04 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This is a cross-sectional, observational study. Patients receiving cardiac surgery in this institution are enrolled and written informed consent for harvesting and using adipose tissue samples is obtained in all patients. After enrollment, clinical and laboratory variables are collected preoperatively, and whole data ware blinded for researchers who perform further experiments. Subcutaneous adipose tissue (1-2 g) is obtained from surgical incision. A part of adipose tissue (50-100 mg) is immediately separated and snap-frozen in liquid nitrogen to study gene expressions. SVF cells are isolated from remained tissue, and analyzed immunophenotypic profile by a flowcytometer. The remained cells after immunophenotyping are cultured and confirmed their proliferative capacity (Colony Forming Unit assay) and angiogenic potential (ELIZA, Tube formation assay, Cell therapy for mice hindlimb ischemia model).


Management information

Registered date

2016 Year 01 Month 27 Day

Last modified on

2020 Year 02 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023911


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name